News & Press

Announcements, publications, and press coverage.

Scientific milestones, platform releases, and interviews. We publish failures alongside successes.

2026 · Featured

Mar 2026 AINN-P1 preprint, Small model, big intelligence: compact sequence-only PLM for VHH fitness bioRxiv 2026 AINN-P1 improves antibody–antigen affinity ranking by 28% from sequence alone BioSpace 2026 Validated program success across 58 antibody maturation campaigns, 28-program biologics pipeline opens for licensing BioSpace 2026 AINN-P1 demonstrates efficient protein prediction and antibody engineering EIN Presswire 2026 Ainnocence brings its protein, antibody, and peptide AI models to production as secure, on-demand APIs BioSpace 2026 Ainnocence proposes a seven-rule governance framework and value scorecard for AI-driven drug discovery BioSpace

2025 · Platforms

2025 PeptideAI platform screens 3.2M peptides with 90%+ accuracy EIN Presswire 2025 CarbonAI®, a proprietary AI engine for de novo small-molecule and PROTAC design EIN Presswire 2025 SentinusAI® goes live, turning sequence data into discovery decisions in days EIN Presswire 2025 Sequence-based AI achieves whole-genome screening for billions of candidates in hours BioSpace 2025 Ainnocence calls for global collaboration on AI-driven antibody and vaccine discovery against the world's deadliest infectious diseases BioSpace 2025 NatmolAI™, computational expansion and optimization of natural-product chemical space EIN Presswire 2025 From code to cure, accelerating oligonucleotide design with AI EIN Presswire 2025 RNA reimagined, harnessing AI to unlock mRNA and siRNA therapies EIN Presswire 2025 AI platform for material performance prediction and process optimization EIN Presswire 2025 Expanding the druggable universe, targeting therapeutics without structural data EIN Presswire 2025 Antibody design at lightning speed, AI-driven precision for complex targets EIN Presswire 2025 Beyond the library, 10¹⁰ virtual compounds and antibody variants screened overnight EIN Presswire 2025 Redefining chemistry, AI shrinks small-molecule discovery from years to weeks EIN Presswire 2025 New milestone with protein foundation models EIN Presswire 2025 SentinusAI® demonstrates consistent superior performance in protein design EIN Presswire 2025 Ainnocence launches BioSynthAI for AI-driven synthetic biology product discovery EIN Presswire 2025 Ainnocence unveils core challenges undermining AI-driven small-molecule drug discovery EIN Presswire 2025 Obatala Sciences and Ainnocence announce partnership, AI with human biological models Partnership

2024 · Foundations

2024 10,000× reduction in computational cost for protein design without 3D modeling EIN Presswire 2024 Breakthrough AI technology for rapid pandemic response EIN Presswire 2024 Computational efficiency breakthrough in therapeutic protein engineering EIN Presswire 2024 Advanced AAV design services for gene therapy EIN Presswire 2024 CellulaAI™ launched, AI engine for CAR-T therapy EIN Presswire 2024 SentinusAI® unveiled, antibody design for undruggable targets EIN Presswire 2024 Green AI and animal-free drug screening, sustainable and ethical commitment EIN Presswire 2024 AI-enabled platform for antibody affinity maturation and GPCR design EIN Presswire

Media & Interviews

Dec 2022 Dr. Lurong Pan featured, how AI that powers chatbots and search queries could discover new drugs Wall Street Journal Talk Protein LLMs and generative AI in protein engineering YouTube Interview Info-Tech thought-leader interview, how AI is used in drug design Info-Tech Podcast BioBuzz with Sino, ChatGPT in biotech Sino Biological Episode 1 Dataiku AI&US, Making the breakthrough Dataiku Talk AI-designed mutation-resistant broad neutralization antibodies against SARS-CoV-2 YouTube Explainer Dr. Lurong Pan answers FAQs about AI in drug discovery YouTube
Media & press inquiries

Writing about AI in drug discovery?

For press, scientific interviews, podcast appearances, or executive bios, reach us directly.

Press contact →